19 Ankylosing Spondylitis Clinical Trials in Fairfax, VA (2026)

Q: How do I join a clinical trial in Fairfax?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you.

Recruiting Ankylosing Spondylitis Studies in Fairfax

NCT07107230Recruiting

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Par...

Fairfax, VAPHASE1380 participantsJanssen Research & Development, LLC

View Study Details

NCT07141706Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up t...

Fairfax, VAPHASE1233 participantsDualityBio Inc.

View Study Details

NCT06993844Recruiting

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors...

Fairfax, VAPHASE1233 participantsEnsem Therapeutics

View Study Details

NCT06759649Recruiting

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid ...

Fairfax, VAPHASE1200 participantsCompugen Ltd

View Study Details

NCT06022029Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expan...

Fairfax, VAPHASE1168 participantsOncoNano Medicine, Inc.

View Study Details

NCT07054515Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann...

Fairfax, VAPHASE3147 participantsAzafaros A.G.

View Study Details

NCT06781983Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanc...

Fairfax, VAPHASE1145 participantsInnate Pharma

View Study Details

NCT06240728Recruiting

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to lear...

Fairfax, VAPHASE1144 participantsNextPoint Therapeutics, Inc.

View Study Details

NCT06270706Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in com...

Fairfax, VAPHASE1124 participantsPliant Therapeutics, Inc.

View Study Details

NCT07407933Recruiting

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untre...

Fairfax, VAPHASE1118 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06663358Recruiting

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine...

Fairfax, VA100 participantsChiesi Farmaceutici S.p.A.

View Study Details

NCT07408089Recruiting

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults wit...

Fairfax, VAPHASE196 participantsBoundless Bio, Inc.

View Study Details

NCT07082725Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Fairfax, VAPHASE372 participantsAzafaros A.G.

View Study Details

NCT06805825Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit....

Fairfax, VAPHASE167 participantsNovelty Nobility, Inc.

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

Fairfax, VAPHASE163 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07524322Recruiting

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RG...

Fairfax, VAPHASE163 participantsRegor Pharmaceuticals Inc.

View Study Details

NCT06788912Recruiting

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether ...

Fairfax, VAPHASE260 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07123155Recruiting

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT....

Fairfax, VAPHASE245 participantsShionogi

View Study Details

NCT07524855Recruiting

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed...

Fairfax, VAPHASE133 participantsHalda Therapeutics OpCo, Inc.

View Study Details

About Ankylosing Spondylitis Clinical Trials in Fairfax

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 19 ankylosing spondylitis clinical trials recruiting participants in Fairfax, VA. These studies are seeking a combined 2,491 participants. Research is being sponsored by Janssen Research & Development, LLC, DualityBio Inc., Ensem Therapeutics and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Fairfax — FAQ

Are there ankylosing spondylitis clinical trials in Fairfax?

Yes, there are 19 ankylosing spondylitis clinical trials currently recruiting in Fairfax, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fairfax?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you about next steps.

Are clinical trials in Fairfax free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairfax studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 19 active trials in Fairfax are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated July 20, 2026 from ClinicalTrials.gov